Real-World Experience With Mogamulizumab for Mycosis Fungoides and Sézary Syndrome
Clinical Lymphoma Myeloma and Leukemia · 2026-11 · 26 (11) · e1278-e1286.e1
DOI: 10.1016/j.clml.2026.08.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026-11. Verfasst von Charalampos Filippatos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Sezary Syndrome, Mycosis Fungoides, Antibodies, Monoclonal, Humanized, Skin Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Mogamulizumab is an established treatment option for relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS); however, large-scale real-world outcome data remain limited. MATERIALS AND METHODS: We conducted a retrospective cohort study on patients with MF or SS who received treatment with mogamulizumab using TriNetX. RESULTS: A total of 394 patients were included (182 [46.2%] MF, 212 [53.8%] SS). The median follow-up was 31.5 months. The 1- and 3-year OS rates were 85.7% and 73.4%, respectively. Corresponding rates among MF and SS patients were 82.0% versus 88.2% and 69.3% versus 76.7%. In univariable analyses, SS was associated with improved OS (Hazard ratio [HR] 0.75, 95% confidence interval [CI] 0.57-0.98; P = .032), whereas nodal involvement predicted inferior survival (HR 1.36, 95% CI 1.01-1.93; P = .043). Following adjustment, both associations were attenuated to non-significant trends (SS: aHR = 0.70, 95% CI: 0.47-1.03, P = .067; nodal involvement: aHR 1.40, 95% CI 0.95-2.06; P = .089). Overall, 154 patients (39.1%) required subsequent systemic therapy, with the 1- and 3-year cumulative incidence being 31.1% (95% CI: 25.7%-35.7%) and 41.0% (95% CI: 35.1%-46.9%), respectively. Elevated LDH independently predicted shorter TTNT (acsHR 1.62, 95% CI 1.29-2.03; P < .001). The 12-month incidences of infection, sepsis, hospitalization, and emergency department visits were 39.8%, 13.5%, 34.3%, and 20.6%, respectively, with similar incidences between MF and SS. CONCLUSIONS: In this large real-world cohort, mogamulizumab was associated with durable survival, prolonged treatment-free intervals, and the outcomes observed were consistent with the pattern seen in the MAVORIC trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
- Clinic and Laboratory of Pathophysiology, Department of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: desfotiou@gmail.com.
Zitieren
APA
Filippatos, C., Gavriatopoulou, M., Briasoulis, A., Ntanasis-Stathopoulos, I., Terpos, E., & Fotiou, D. (2026). Real-World Experience With Mogamulizumab for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma and Leukemia, 26(11), e1278-e1286.e1. https://doi.org/10.1016/j.clml.2026.08.018
Vancouver
Filippatos C, Gavriatopoulou M, Briasoulis A, Ntanasis-Stathopoulos I, Terpos E, Fotiou D. Real-World Experience With Mogamulizumab for Mycosis Fungoides and Sézary Syndrome. Clinical Lymphoma Myeloma and Leukemia. 2026;26(11):e1278-e1286.e1. doi:10.1016/j.clml.2026.08.018
BibTeX
@article{Filippatos2026,
author = {Filippatos, Charalampos and Gavriatopoulou, Maria and Briasoulis, Alexandros and Ntanasis-Stathopoulos, Ioannis and Terpos, Evangelos and Fotiou, Despina},
title = {Real-World Experience With Mogamulizumab for Mycosis Fungoides and Sézary Syndrome},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
volume = {26},
number = {11},
pages = {e1278--e1286.e1},
doi = {10.1016/j.clml.2026.08.018}
}
EUVIMED